New AI Model LFM2-2.6B-MMAI Speeds Up Drug Discovery

Liquid AI and Insilico Medicine partnered to launch LFM2-2.6B-MMAI, a foundation model for drug discovery ^[1]. This 2.6 billion parameter model matches the performance of larger systems in pharmaceutical tasks ^[2]. It is specifically built to run on private infrastructure, ensuring data security for researchers ^[1]. The model aims to streamline end-to-end drug discovery processes by reducing computational requirements ^[3]. By utilizing a lightweight architecture, it allows smaller labs to access advanced AI capabilities ^[2]. This development marks a shift toward efficient, high-performance models in the biotech industry ^[3].